SCHEMBL10116280

SCHEMBL10116280

CC(C)(C)S(=O)(=O)Nc1ccc(C(=O)Nc2cccc(C(N)=O)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.60
KCNK9 Q9NPC2 2/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
KMT2A Q03164 3/20 0.50
POLB P06746 1/20 0.50
MEN1 O00255 2/20 0.49
KDM4E B2RXH2 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
HPSE Q9Y251 1/20 0.48
ALDH1A1 P00352 1/20 0.47
PARP1 P09874 3/20 0.47
PARP10 Q53GL7 3/20 0.47
KCNK3 O14649 2/20 0.47
PARP15 Q460N3 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PARP14 Q460N5 1/20 0.46
PLAU P00749 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10114497 0.84 HPGD (0.56) HPGDKCNK9KMT2APOLBMEN1
SCHEMBL10116200 0.84 NPC1 (0.59) HPGDKCNK9KMT2AMEN1KDM4E
SCHEMBL10116221 0.84 ADORA3 (0.64) HPGDKCNK9CA1KMT2AMEN1
SCHEMBL10116391 0.83 HPGD (0.55) HPGDKCNK9CA1CA2KMT2A
SCHEMBL10116182 0.83 KMT2A (0.57) HPGDKMT2APOLBMEN1KDM4E
SCHEMBL10116566 0.82 HPGD (0.60) HPGDKMT2APOLBMEN1KDM4E
SCHEMBL10116240 0.82 MEN1 (0.55) CA1CA2KMT2APOLBMEN1
SCHEMBL10116339 0.81 MAPT (0.61) KCNK9KMT2AMEN1KCNK3HDAC3
SCHEMBL13762080 0.81 KCNK9 (0.76) KCNK9CA1CA2KMT2AMEN1
SCHEMBL17090552 0.81 HDAC1 (0.50) KMT2AMEN1PARP1PARP10HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R HPGD 3487/4885KCNK9 1442/4885CA1 1908/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R HPGD 3475/4885KCNK9 1479/4885CA1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.